Compare Intel Corp (INTC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Mesoblast Limited — how do they compare? Intel Corp trades at $98.99 (market cap $492.85B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Intel Corp is far larger — about 223× Mesoblast Limited's market cap, and Intel Corp pays a 2.24% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| INTC | MESO | |
|---|---|---|
Market Cap | $492.85B | $2.21B |
Volume | 43,552,012 | — |
Sector | Technology | Technology |
52-Week High | $140.94 | $20.96 |
52-Week Low | $21.81 | $12.88 |
Enterprise Value | $513.66B | $2.21B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.52, down 4.06% today amid a $20 billion stock offering announcement. Despite recent earnings beats, the stock faces pressure from dilution concerns while showing strong revenue growth in data center and AI segments. Technical indicators are bullish on moving averages but neutral on oscillators, with key resistance at $100. Fundamentals reveal a mixed picture with negative net income margins but improving operational cash flow trends.
The outlook remains cautiously optimistic with a $116.67 analyst price target suggesting 20% upside, though execution risks in foundry losses and competitive pressures persist. Investors should weigh the growth potential in AI against near-term dilution and margin challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
